Search
Tienilic acid
go.drugbank.com/drugs/DB04831ApprovedWithdrawnTienilic acid, or ticrynafen, is a diuretic drug with uric acid-lowering action which was marketed for the treatment of hypertension. … It was withdrawn in 1982 after case reports in the United States suggested a link between ticrynafen and hepatitis. (Manier et al., 1982)
Etripamil
go.drugbank.com/drugs/DB12605ApprovedInvestigationalEtripamil is a nondihydropyridine, L-type calcium channel blocker.[A275238, L54728] It is a fast-acting drug with a short duration of action. … [A275243, A275248] The nasal formulation of etripamil was first approved by the FDA on December 12, 2025 for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT
Scarlet red
go.drugbank.com/drugs/DB19136ApprovedWithdrawnScarlet red is under investigation in clinical trial NCT00591916 (New Treatment for Donor Sites).
Categories: Compounds used in a research, industrial, or household settingBenzonatate
go.drugbank.com/drugs/DB00868Approved[L11193] Although it not prone to drug misuse or abuse, benzonatate is associated with a risk for severe toxicity and overdose, especially in children.[A189513] … [A5790] Currently, benzonatate is the only non-narcotic antitussive available as a prescription drug.
Andusomeran
go.drugbank.com/drugs/DB18227ApprovedInvestigationalAndusomeran is a COVID-19 mRNA vaccine developed for use during the 2023-2024 season.[L40074,L48832,L48837] It is similar to previous mRNA vaccines developed by Moderna (e.g.
Apalutamide
go.drugbank.com/drugs/DB11901ApprovedInvestigationalIn a randomized trial, the median metastasis-free survival for patients taking apalutamide was 40.5 months compared to 16.2 months for patients taking a placebo [L1295]. … Higher prostate-specific antigen (PSA) and shorter PSA doubling time (PSA DT) are associated with a higher risk for metastases and death [A31846].
Tradipitant
go.drugbank.com/drugs/DB12580ApprovedInvestigationalTradipitant is a selective, high-affinity antagonist at human substance P/neurokinin-1 (NK-1) receptors. … [A275353] Approved by the FDA on December 30, 2025, tradipitant is indicated for the prevention of vomiting induced by motion.
Loteprednol etabonate
go.drugbank.com/drugs/DB14596ApprovedAs a nasal spray, it can be used for the treatment and management of seasonal allergic rhinitis. … Loteprednol Etabonate (LE) is a topical corticoid anti-inflammatory.
Nivolumab
go.drugbank.com/drugs/DB09035ApprovedInvestigationalNivolumab is a fully human IgG4 antibody targeting the immune checkpoint programmed death receptor-1 (PD-1). … [L12129] This antibody was produced entirely in mice and grafted onto human kappa and IgG4 Fc region with the mutation _S228P_ for additional stability and reduced variability.
Categories: PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitorsProducts: OPDIVO CONCENTRATE FOR SOLUTION FOR INFUSION 10 MG/ML, Opdivo 10mg/ml, Concentrate for solution for infusionElafibranor
go.drugbank.com/drugs/DB05187ApprovedInvestigationalElafibranor is a dual peroxisome proliferator-activated receptor (PPAR) α and β/δ agonist [A263833] that works to inhibit bile acid synthesis. … [L50768] On June 10, 2024, elafibranor was granted accelerated approval by the FDA for the treatment of primary biliary cholangitis (PBC).